A REVIEW OF MOUNJARO INJECTION 5 MG

The trial accomplished both of those its Principal endpoints, with semaglutide two.4 mg demonstrating statistically substantial and excellent improvements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH when compared with placebo.oneI